You are here

RSV

With FDA decision penciled in for May, GSK powers ahead in RSV race with Pfizer

Fierce Biotech

Wed, 11/2/22 - 10:25 am

After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

CNN

Tue, 11/1/22 - 12:12 pm

maternal vaccines

clinical trials

GSK hits back in high-stakes RSV vaccine game, posting phase 3 data that suggest it has edge on Pfizer

Fierce Biotech

Thu, 10/13/22 - 09:47 am

clinical trials

Moderna Therapeutics

Sanofi, AstraZeneca win EMA support for RSV drug in babies

BioPharma Dive

Sun, 09/18/22 - 10:22 pm

Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms

Fierce Pharma

Fri, 09/16/22 - 10:54 am

Pfizer heads to the FDA with an early lead over rivals in the $10B RSV vaccine market

Endpoints

Thu, 08/25/22 - 11:27 am

Moderna CEO touts plan for triple combo respiratory shot in 'three to five years': report

Fierce Pharma

Thu, 08/11/22 - 11:53 am

Moderna Therapeutics

Stephane Bancel

triple combo vaccine

Pfizer seeks to overturn three RSV vaccine patents held by GSK

Pharmaforum

Wed, 06/29/22 - 05:30 pm

GSK hails phase 3 win for RSV vaccine in older adults, sparking race to regulators

Fierce Biotech

Fri, 06/10/22 - 10:45 am

clinical trials

Enanta sinks to multiyear low as phase 2b RSV trial flames out

Fierce Biotech

Thu, 05/19/22 - 10:45 am

Enanta Pharmaceuticals

clinical trials

LabCorp becomes first company to get EUA for direct-to-consumer test for flu, RSV, COVID-19

Medtech Dive

Wed, 05/18/22 - 10:14 am

Emergency Use Authorization

Starna Therapeutics emerges with financing for mRNA vaccine and therapies

Endpoints

Mon, 05/16/22 - 10:38 am

Starna Therapeutics

idiopathic pulmonary fibrosis

AZ, Sanofi build case for one-shot RSV antibody

Pharmaforum

Wed, 05/11/22 - 10:31 am

Pfizer nabs RSV therapeutic biotech ReViral in quick $525M bolt-on

Fierce Biotech

Thu, 04/7/22 - 10:29 am

Big pharma’s key second-quarter data

EP Vantage

Tue, 03/29/22 - 10:32 am

Pfizer grabs another breakthrough tag for RSV shot in older adults

Fierce Biotech

Thu, 03/24/22 - 11:05 am

breakthrough designation

Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseases

Fierce Biotech

Tue, 03/22/22 - 10:49 am

Moderna Therapeutics

Small RSV contender eyes 'first-to-market' opportunity with $225M Asia deal

Endpoints

Mon, 03/21/22 - 10:13 am

Bavarian Nordic

Glaxo holds its breath

EP Vantage

Thu, 03/17/22 - 10:17 am

clinical trials

Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results

BioSpace

Thu, 03/3/22 - 10:24 am

clinical trials

Pages